Researchers at City of Hope® and the University of California, Berkeley have developed a new microfluidic platform that can assess breast cancer risk at the cellular level by compressing individual breast epithelial cells.
The platform, described as the first of its kind, applies mechanical compression to single cells, creating measurable changes that correlate with cancer risk. This approach offers a novel way to evaluate cellular behavior under physical stress, which may reflect early signs of malignancy.
According to the research team, the technology enables precise, real-time analysis of how cells respond to compression, providing insights that traditional imaging or genetic tests might miss. By focusing on the mechanical properties of cells, the method adds a functional dimension to risk assessment.
The development represents a significant step forward in personalized cancer screening, particularly for women with a family history or genetic predisposition to breast cancer. Early detection at the cellular level could improve intervention strategies before tumors become visible through conventional means.
Whereas still in the experimental phase, the microfluidic tool has shown promise in laboratory studies for distinguishing between normal and high-risk cell phenotypes based on their mechanical response. Researchers believe this could eventually complement existing screening methods like mammography and genetic testing.
The innovation highlights the growing role of biophysical markers in cancer diagnostics and underscores the potential of microfluidics to transform how we detect and monitor disease at the earliest stages.
